Online inquiry

IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9142MR)

This product GTTS-WQ9142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9142MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7776MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ5013MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ13403MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ14320MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ11764MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ5768MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8753MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ14874MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW